Table 2 First and second-line targeted drugs used in the present cohort
First targeted therapy | Second targeted therapy | ||||||
|---|---|---|---|---|---|---|---|
Everolimus (n = 520) | Sorafenib (n = 240) | Sunitinib (n = 228) | Axitinib (n = 29) | Pazopanib (n = 10) | Temsirolimus (n = 1) | Bevacizumab + IFN (n = 1) | |
Bevacizumab + IFN | 5 (1.0%) | 4 (1.7%) | 19 (8.3%) | 0 (0.0%) | 7 (70.0%) | 0 (0.0%) | 0 (0.0%) |
Sorafenib | 93 (17.9%) | 0 (0.0%) | 139 (61.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Sunitinib | 390 (75.0%) | 232 (96.7%) | 0 (0.0%) | 28 (96.6%) | 3 (30.0%) | 1 (100.0%) | 1 (100.0%) |
Temsirolimus | 0 (0.0%) | 2 (0.8%) | 21 (9.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Pazopanib | 32 (6.2%) | 2 (0.8%) | 49 (21.5%) | 1 (3.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |